Interactive veterinary neurology-neuropathology workshop
W. Baumgärtner, A. Beineke, A. Oevermann, V. Stein
Veterinary dermatopathology workshop.
Standardization of Gastro-Intestinal biopsies
Wild animals emerging and reemerging diseases as reservoirs.
S. Benestad,. MA. Jiménez
Poster, oral presentations and copyright matters.
A. Groene, L. Peña
How to make good pictures for publication.
ECVP Board examination : training the trainees
Tuesday 29th and Wednesday 30th August
1. Davis Thompson Foundation 2017, European Division Pathology Symposium
Exploring lymphoma in domestic animals
Topics in lymphoma will include:
- The diagnostic approach to the WHO Classification System of Lymphomas
- Advanced diagnostic testing in lymphoma/leukemia
- Canine lymphoma – The most common and not so common subtypes, indolent versus aggressive lymphomas, splenic nodules, and more
- Feline Lymphoma – Types of gastrointestinal lymphomas and less common subtypes such as Hodgkin-like lymphoma, cutaneous lymphocytosis, nasal lymphoma and primary solitary ocular lymphoma
- Equine Lymphoma – All about T-cell rich large B-cell lymphomas
- Histiocytic disorders – A potential diagnostic pitfall for lymphoma
In addition, there will be interactive case discussions each day.
For more information and registration click here.
Monday 28th and Tuesday 29th August
2. Société Franćaise d’Anatomie Pathologique Vétérinaire (SFAPV)
The annual scientific meeting will be held on monday 28th and tuesday 29th of August.
The SFAPV is very pleased to have Pr Verena Affolter and Dr Kerstin Bergvall as our invited expert pathologist and dermatologist this year for our annual seminar.
This one and a half-day workshop will allow participants to discuss a variety of dermatopathology cases with the speakers and share their experience. Participants will enjoy the cases through digital microscopy, as well as lectures.
All attendees are kindly requested to provide non-tumoral dermatopathology cases from their own daily practice in canine or feline histopathology. The submitted cases should include complete clinical history, gross pictures, stained histological slides and potentially unstained slides for ancillary methods. Digitalized sections will be used during the seminar.
The dead-line for case submission is 30th June 2017. For further details please see our website: www.sfapv.com
Wednesday 30th August
Tox21 Implications for Toxicologic Pathology
This 4-hour session will discuss toxicologic pathology in the 21st century and the role of the pathologist in the era of “omics”, high throughput screening, and alternative in vitro testing. The session will cover molecular tools and technologies available to pathologists and toxicologists, in vitro models and approaches used in modern pathology, adverse outcome pathways, and the challenges pathologists face in correlating molecular outcomes with histopathology findings in toxicity testing. A panel discussion will convene at the end of the speaker presentations to engage the audience on how these new approaches may be implemented in toxicologic pathology.
8:00 – 8:30 AM
Darlene Dixon, NIEHS, NTP – The Tool Box for the Molecular Pathologist
8:30 – 9:15 AM
Bridgette Landesmann, ECVAM – In vitro approaches to modern toxicology: Where are we and where are we going?
9:15 – 10:00 AM
Arun Pandiri, NIEHS, NTP – Adverse Outcome Pathways: A Pathologist’s Perspective
10:00-10:30 AM Break
10:30-11: 15 AM
Alessandro Piaia (presenter), Novartis with Frieke Kuper, TNO – When morphology meets omics –are gene expression profiling and histopathology truly complementary in toxicity assessments?
Moderators: Darlene Dixon, NIEHS, NTP and Thomas Lemarchand, TPL Path Labs – Panel Discussion (Speakers and Participants)
Title: The Toolbox for the Molecular Pathologist
With the advent of more molecular based assays, high-throughput screening, and in vitro approaches being used in toxicologic assessments, the pathologist in the 21st century is faced with great opportunity and challenges. This presentation will give a perspective on the role of the toxicologic pathologist in the ToxPath21 era. The use of molecular and mechanistic approaches to further define histopathology findings, and some molecular tools available to the pathologist that can be applied to tissue-based and in vitro analyses will be discussed.
Title: In Vitro Approaches to Modern Toxicology: Where Are We and Where Are We Going?
Animal models are still widely used in toxicity testing and biomedical research, but it is increasingly recognised that animals are not a good model for human pathologies. Besides ethical considerations the uncertain predictability of animal testing for human adverse health effects is a limiting factor in chemical risk assessment. Moreover, due to costs and time involved, it is not feasible to use these methods for testing all the chemicals that could affect human health. “Toxicity testing in the twenty-first century” aims to understand the underlying mechanisms of toxicity, rather than rely on direct observations of toxic effects. Improved mechanistic knowledge enables the development of integrated testing strategies, which rely on using in vitro methods, preferably based on human cells or human cell constituents that in combination with in silico approaches facilitate in vivo predictions of toxicity and chemical risk assessment.
Studies with cultured human cells, including primary cells, established cell lines, and, more recently, induced pluripotent stem cells (iPSCs) are increasingly done. However, two-dimensional cell culture systems do not adequately mimic tissue and organ-level structures and functions. Therefore, more physiologically complex and relevant cell culture formats, like three-dimensional, multicellular, “organotypic” models have been produced, which mimic functional responses of living tissue. Even more sophisticated “organ-on-a-chip” cell culture devices can mimic physico-chemical microenvironments and vascular perfusion characteristics.
Each of these models has its drawbacks and none truly reflects the manifold ongoing processes in human disease. Clinical samples from healthy persons and from patients could be used as benchmark for a better understanding and improved relevance of in vitro testing. Various models and their relevance and utility for predicting human pathology will be discussed.
Title: Adverse Outcome Pathway (AOP) – A Pathologist’s Perspective
An Adverse outcome pathway (AOP) contains a sequential progression of causally linked pathophysiological mechanistic events across increasingly complex biological systems that lead to an adverse outcome. AOPs leverage the cellular signaling pathway information obtained from various data sources, such as high-throughput in vitro data, toxicogenomics, and systems biology, to predict the eventual adverse phenotype in vivo (apical endpoint) for decisions on product development and regulatory purposes. This presentation will provide an overview of the AOP development and application for identifying a potential hazard. Some of the AOPs that have been well characterized are relatively linear and non animal based tests have been successfully developed to detect the adverse effect. However, most of the biological adverse responses are made of networks and present a challenge to develop a complete AOP. This presentation will discuss some of the success stories and some challenges. Finally, a discussion on the opportunities for a toxicologic pathologist in contributing to the development of AOPs will be presented.
Title: When Morphology Meets Omics – Gene Expression Profiling and Histopathology Are Truly Complementary in Toxicity Assessments
The establishment of technologies in profiling gene expression to monitor changes at cellular levels has tremendously enhanced our knowledge on the nature of test-item-related changes in toxicology. Histopathology has profited from the integration of the observations with the genomic expression profile, however the relationship between the two disciplines is far more integrative and reciprocally dependent than what can be seen at a first glance.
Three examples (one oral rat study with histology and genomics in multiple endocrine organs, one dog inhalation study with lung changes and one rat asthma model for inhalation treatment), are presented to show different levels of integration of the data between the two disciplines and how and where each discipline could complement the other.